May 22 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in a move that coincides with a deadline ...

Novo Nordisk is offering self-paying patients who are new to Wegovy their first month of medicine for $199 through June 30, 2025. For subsequent months, self-pay patients will pay $499 per month.